Crystalline forms of AP26113, and preparation method thereof
First Claim
Patent Images
1. A crystalline form CS2 of brigatinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 17.1°
- ±
0.2°
, 22.9°
±
0.2° and
28.7°
±
0.2°
using CuKα
radiation.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to two novel crystalline forms of AP26113 and processes for preparation thereof. The crystalline form CS1 and crystalline form CS2 of the present disclosure have advantages in solubility and stability, are suitable for development, and provide a better choice for preparation of pharmaceutical compositions containing AP26113, which is of great significance for drug development.
-
Citations
14 Claims
-
1. A crystalline form CS2 of brigatinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 17.1°
- ±
0.2°
, 22.9°
±
0.2° and
28.7°
±
0.2°
using CuKα
radiation. - View Dependent Claims (2, 3, 4, 5, 11, 12)
- ±
-
6. A crystalline form CS1 of brigatinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 5.5°
- ±
0.2°
, 21.6°
±
0.2° and
10.8°
±
0.2°
using CuKα
radiation. - View Dependent Claims (7, 8, 9, 10, 13, 14)
- ±
Specification